News
Press Releases
Oct 15, 2020BrainStorm Announces Financial Results for the Third Quarter of 2020 and Provides a Corporate UpdatePivotal Phase 3 ALS trial remains on track for top-line data readout by the end of November 2020BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the third quarter ended September...
- Oct 12, 2020
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Stacy Lindborg, Ph.D., Executive Vice President...
- Oct 2, 2020
BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the...
- Sep 30, 2020Presentation outlines design of pivotal Phase 3 trial evaluating NurOwn® as a treatment for ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced the presentation of a poster titled, "Advancing...
- Sep 29, 2020Company continues building its executive team and commercial capabilities prior to ALS Phase 3 clinical trial completion and topline data readout in Q4 2020
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the appointment of William K. White as senior...